X4 Pharmaceuticals, Inc. (XFOR): Price and Financial Metrics
GET POWR RATINGS... FREE!
XFOR Stock Price Chart Interactive Chart >
XFOR Price/Volume Stats
|Current price||$1.23||52-week high||$9.90|
|Prev. close||$1.30||52-week low||$1.00|
|Day high||$1.40||Avg. volume||339,510|
|50-day MA||$1.50||Dividend yield||N/A|
|200-day MA||$3.15||Market Cap||37.91M|
X4 Pharmaceuticals, Inc. (XFOR) Company Bio
X4 Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The Company specializes in developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases including primary immunodeficiencies and cancer. X4's oral small molecule drug candidates antagonize the CXCR4 pathway which plays a central role in immune surveillance.
Most Popular Stories View All
XFOR Latest News Stream
|Loading, please wait...|
XFOR Latest Social Stream
View Full XFOR Social Stream
Latest XFOR News From Around the Web
Below are the latest news stories about X4 Pharmaceuticals Inc that investors may wish to consider to help them evaluate XFOR as an investment opportunity.
BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, today announced that management will participate in a fireside chat at B. Riley Securities Oncology Investor Conference on Friday, January 28, 2022. Details are as follows:Conference: B. Riley Securities Oncology Investor Conference Format: Fireside Chat Date: Friday,
BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, today announced that, on December 31, 2021, the Compensation Committee of X4s Board of Directors issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the 2019 Inducement Plan). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 37,650 shares of X4s common stock. These stock awards were granted as an inducement material to the new employees enterin...
During the last session, X4 Pharmaceuticals Inc. (NASDAQ:XFOR)’s traded shares were 1.29 million, with the beta value of the company hitting 0.43. At the end of the trading day, the stock’s price was $2.37, reflecting an intraday gain of 17.33% or $0.35. The 52-week high for the XFOR share is $10.70, that puts it down … X4 Pharmaceuticals Inc. (NASDAQ: XFOR) Drops -351.48% From Highs, Now What? Read More »
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on X4 Pharmaceuticals (XFOR – Research Report) today and set a price target of $10.00. The company's shares closed last Wednesday at $1.95, close to its 52-week low of $1.88. According to TipRanks.com, Mamtani is a 1-star analyst with an average return of -0.3% and a 36.3% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for X4 Pharmaceuticals with a $13.00 average price target, a 587.8% upside from current levels. In a report released yesterday, H.C.
X4 Pharmaceuticals had its price target cut by HC Wainwright from $21.00 to $11.00 in a research note published on Tuesday, The Fly reports. They currently have a buy rating on
XFOR Price Returns
Continue Researching XFORWant to see what other sources are saying about X4 Pharmaceuticals Inc's financials and stock price? Try the links below:
X4 Pharmaceuticals Inc (XFOR) Stock Price | Nasdaq
X4 Pharmaceuticals Inc (XFOR) Stock Quote, History and News - Yahoo Finance
X4 Pharmaceuticals Inc (XFOR) Stock Price and Basic Information | MarketWatch